Business Wire

Key sub-analyses of RE-DUAL PCI™ showed large reductions in the incidence of bleeding complications if Pradaxa® (dabigatran etexilate) dual therapy was used instead of warfarin triple therapy

Jaa

Boehringer Ingelheim has shared sub-analyses from the RE-DUAL PCI™ clinical trial at the AHA Scientific Sessions 2017 in Anaheim, California. RE-DUAL PCI™ investigated different treatment approaches in patients with non-valvular atrial fibrillation (AF) following percutaneous coronary intervention (PCI) with stent placement. Anticoagulation using dual therapy with dabigatran etexilate (marketed as Pradaxa®) and a single antiplatelet without aspirin was compared to triple therapy with warfarin. The new sub-analyses presented showed very consistent benefits of dual therapy with dabigatran across different pre-specified groups of patients, including:1

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171115005597/en/

  • Patients using different antiplatelet therapies (P2Y12 inhibitors ticagrelor or clopidogrel)
  • Patients presenting with either acute coronary syndrome (ACS) or patients with no ACS
  • Patients receiving a drug-eluting stent or a bare-metal stent

PCI with stenting is undertaken to improve the blood flow to the heart. It may be required in 20-30% of AF patients who already take an oral anticoagulant to reduce their risk of stroke.2 The current combination of potent antithrombotic therapies, which is triple therapy with warfarin and two antiplatelets, is associated with high rates of major bleeding.3-6 The main results of RE-DUAL PCI™7,8 were presented at this year’s ESC Congress and published in the New England Journal of Medicine. They showed significantly lower rates of major or clinically relevant non-major bleeding events for dual therapy with dabigatran compared to triple therapy with warfarin. The rates of overall thromboembolic events were similar.

“When treating AF patients after PCI with stenting, it is important to understand how different clinical variables like if the patient had an acute coronary syndrome, the choice of stent type, or the choice of concomitant antiplatelet may influence the outcomes,” explained Professor Jonas Oldgren, Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden. “The additional analyses of the RE-DUAL PCI trial, which we have presented at the AHA Scientific Sessions in Anaheim, showed that the results for dual therapy with dabigatran in these sub-groups are consistent with the overall results of the trial.”

The overall results for RE-DUAL PCI™ were:7,8

  • Incidence of primary endpoint (time to major or clinically relevant non-major bleeding event):
    • 48% lower for dabigatran 110 mg dual therapy
    • 28% lower for dabigatran 150 mg dual therapy (relative difference)
  • Similar rates of overall thromboembolic events for both doses of dabigatran dual therapy compared to warfarin triple therapy, the key secondary endpoints

“We set out to answer the relevant questions physicians have when it comes to anticoagulation in patients with a stent,” commented Professor Jörg Kreuzer, Vice President Medicine, Therapeutic Area Cardiovascular, Boehringer Ingelheim. “The sub-analyses from RE-DUAL PCI™ now reinforce the impressive results from the entire RE-DUAL population. Also in the sub-groups, a significantly better benefit-risk profile of dual therapy with dabigatran compared to triple therapy with warfarin was demonstrated.”

~ENDS~

Please click on the link for ‘Notes to Editors’ and ‘References’: http://www.boehringer-ingelheim.com/RE-DUAL-PCI-sub-analysis-data-presented-at-AHA-2017

For more information, please visit:  www.boehringer-ingelheim.com

Further Media Channels

www.facebook.com/boehringeringelheim

www.twitter.com/Boehringer

Contact information

Boehringer Ingelheim GmbH
Corporate Communications
Media + PR
Friederike Middeke
Phone: +49 6132 – 77 141575
Fax: +49 6132 – 77 6601
E-mail:  press@boehringer-ingelheim.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

OCP Announces Date of 2017 Third Quarter and Nine Month Results22.11.2017 19:59Tiedote

OCP S.A., a global leader in the fertilizer industry, will release its third quarter and nine month 2017 results on Thursday, November 30, 2017. The results will be available to holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers on the OCP Intralinks portal at 9 a.m. EDT and 2 p.m. Morocco/London time. OCP senior management will host a conference call to discuss 2017 third quarter/nine month results at 10 a.m. EDT and 3 p.m. Morocco/London time on Thursday, November 30, 2017 for holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers. Eligible parties that have not already registered for access to the Intralinks portal may do so by contacting the Investor Relations Department by emailing g.laraki@ocpgroup.ma. About OCP OCP is a global leader in the fert

Tata Motors Charts Out 'Connecting Aspirations' As Its New Corporate Brand Identity in Global Markets22.11.2017 17:46Tiedote

As part of the company’s transformation journey undertaken in 2016, Tata Motors commenced a comprehensive project to articulate its corporate branding. Basis a thorough analysis of the existing and the desired future state of the Company, Tata Motors has defined its new brand identity as ‘Connecting Aspirations’ across 46 markets, internationally. ‘Connecting Aspirations’, as the new defining maxim, represents the personality of the brand as an interconnected system of mobility solutions, that are intelligent, perceptive, warm and expressive. It’s a symbolic tagline that represents the company’s past, present and future. It is humble yet bold, a statement as well as a challenge. It will define the way Tata Motors communicates with its internal as well as external stakeholders, and work as an all-encompassing guiding principle across business units.” Speaking on the

NelsonHall Positions L&T Technology Services in the Leaders Category for IoT Services22.11.2017 16:50Tiedote

L&T Technology Services Limited (NSE: LTTS), a leading global pure-play engineering services company announced that it has been positioned in the Leaders Category by independent global research firm, NelsonHall in its latest NEAT evaluation for Internet of Things (IoT) services providers. LTTS is the only global pure-play engineering services to be positioned in the leader’s category. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171122005331/en/ L&T Technology Services Capabilities across IoT Services. (Graphic: Business Wire) LTTS has been identified as a leader relative to its peers’ due to its ability to meet future client requirements as well as deliver immediate benefits to IoT Services clients. Dominique Raviart, IT Services Practice Director, NelsonHall said, “L&T Technol

Smithers Viscient Europe Appoints Alasdair Clipston Director of Chemistry.22.11.2017 13:30Tiedote

Smithers Viscient, a global contract research organisation (CRO), announced the appointment of Alasdair Clipston to the role of Director of Chemistry. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171122005035/en/ Smithers Viscient Europe Appoints Alasdair Clipston Director of Chemistry. (Photo: Business Wire) Clipston joins Smithers with 15 years spent within contract research and testing organisations including AstraZeneca and Charles River. “Alasdair brings great knowledge and experience to our operational leadership team, particularly in residue and physical chemistry including five batch analysis.” said Steve Dean, Managing Director, Smithers Viscient Europe. Dean continues, “His skills and passion for science coupled with excellent client relationships and strong business unde

Mundipharma and APR Applied Pharma Research S.A Announce a New Alliance for the Distribution of Nexodyn® AcidOxidizing Solution in Africa and the Levant22.11.2017 13:30Tiedote

Mundipharma International Corporation Limited (Mundipharma) and APR Applied Pharma Research SA (APR) announce that they have signed a licensing, distribution and marketing agreement for Africa and the Levant Region for the innovative active wound cleanser Nexodyn® AcidOxidizing Solution AOS (Nexodyn® AOS), currently marketed in Europe, Turkey and soon available in Middle East countries. Mundipharma will have exclusive rights to the product in more than 35 African markets and countries of the Levant including Nigeria, Kenya, Egypt, Algeria, Lebanon, Jordan, Tunisia and Morocco. The first launches in these markets will begin in the incoming months following the registration and the obtaining of local authorizations for tariffs and refunds. The global advanced wound care market is expected to grow significantly in the next years as a result of the increasing incidence

The .eu Web Awards Shine Again in 2017 with the Announcement of the Winners22.11.2017 12:00Tiedote

Similar to each of the past 3 years during the month of November, the .eu Web Awards gala generates buzz within the .eu community and domain name industry as a whole. The annual .eu Web Awards, launched in 2014, is a competition where .eu and .ею websites have the chance to be nominated for an opportunity to win an awards package that adds credibility and visibility to their online activity. Of the 15 final nominees, a distinguished jury of European stakeholders chooses the best website in each of the Awards’ five categories. The #2017euWA winners were unveiled at the .eu Web Awards gala that took place yesterday evening at the Theatre du Vaudeville in the heart of Brussels, Belgium. The winners and the special commendations represent an eclectic group, and come from all over the European Union, including Bulgaria (Krina.eu), Latvia (Muniocandela.eu & Letthejourneybegin.eu), Sweden

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme